Clinical Trials

Search Form

Disease Site Trial Sort descending Trial Description Trial Status Lead Cooperative Group

A multicenter phase III randomized study with second line chemotherapy plus or minus bevacizumab in patients with platinum sensitive epithelial ovarian cancer recurrence after a bevacizumab/chemotherapy first line

Completed MITO
Ovarian MITO 25.1

A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-
Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.

Closed to Recruitment MITO
Ovarian MITO12

Pathway to diagnosis of ovarian cancer: an observational retrospective multicentred study 

Completed MITO
Ovarian MITO23

Randomized phase III  trial on  Trabectedin (ET 743) vs clinician’s choice chemotherapy   in recurrent ovarian, primary peritoneal or fallopian tube cancers of BRCA mutated or  BRCAness phenotype patients 

Completed MITO
Ovarian MITO7

First line weekly carboplatin and paclitaxel versus every 3 weeks carboplatin/paclitaxel in patients with ovarian cancer: phase III multicentre trial 

Completed MITO
Ovarian MOCCA

A Multicentre Phase II Randomised Trial of Durvalumab (MEDI4736) Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas

Completed GCGS
Ovarian NIRVANA-1

A Randomized Study of Paclitaxel – Carboplatin followed by maintenance Niraparib compared to Paclitaxel – Carboplatin – Bevacizumab followed by maintenance Niraparib + Bevacizumab in Patients With Advanced Ovarian Cancer, Following a Front-Line Complete Cytoreductive Surgery

Recruiting GINECO

Characterization of High-Grade Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype – A Prospective Observational Study

Recruiting NSGO-CTU
Ovarian PAOLA-1

Platine, Avastin and Olaparib in 1st line Ovarian Cancer

Completed GINECO
Ovarian PMHC – eVolve-1 / OZM-060

A Proof of Concept, Multi-centre, Clinical Trial of the Combination Cediranib-Olaparib at the Time of Disease Progression on PARP Inhibitor in Ovarian Cancer 

Closed to Recruitment PMHC
Ovarian PMHC – NEO / OZM-058

A Phase II, Open-Label, Randomized, Multi-Centre Study of Neoadjuvant Olaparib in Patients with Platinum Sensitive Recurrent High Grade Serous Ovarian/Primary Peritoneal or Fallopian tube Cancer

Closed to Recruitment PMHC

A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVage weekly dose-dense regimen in patients with poor prognostic OVARian cancers based on the tumor primary chemosensitivity and incomplete debulking surgery

Pending GINECO

A Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer(SUNNY)

Recruiting SGOG
Ovarian Tarceva Trial EORTC 55041

A randomised, multicentre, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

Completed EORTC-GCG
Ovarian TEDOVA

OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Recruiting GINECO
Ovarian & Endometrial Primary LARA

A Multicentre Phase II trial of  Lenvatinib plus PembrolizumAb in Recurrent gynaecological clear cell Adenocarcinomas

Recruiting GCGS
Ovarian Clear Cell GCIG/JGOG3017

Randomized Phase III Trial of Paclitaxel plus Carboplatin (TC) Therapy versus Irinotecan plus Cisplatin (CPT-P) Therapy as a First Line Chemotherapy for Clear Cell Carcinoma of the Ovary 

Completed JGOG
Ovarian Newly Diagnosed ENGOT-ov43/GOG-3036/MK-7339

A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) 

Closed to Recruitment BGOG

Efficacy and Safety of Bevacizumab (Avastin) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours

Completed GINECO
Ovarian/Rare ROCSAN

A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy

Recruiting GINECO